Douglas Treco, Ph.D.President, CEO and Co-Founder at Ra Pharmaceuticals, Inc.
Dr. Treco received a PhD degree in Biochemistry and Molecular Biology from SUNY at Stony Brook and performed post-doctoral studies at the Salk Institute and Massachusetts General Hospital. In 1988 he co-founded Transkaryotic Therapies, Inc. (TKT, acquired in 2005 by Shire plc), where he established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. He has been the CEO of Ra Pharmaceuticals since its inception and serves on the Company’s Board of Directors. He has authored numerous peer-reviewed publications and holds over 50 US and European patents in the areas of protein and peptide production, gene mapping, and gene therapy.